Myeloproliferative neoplasm epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:


===Age===
===Age===
The prevalence of myeloproliferative neoplasm increases with age.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215  }} </ref>
The prevalence of myeloproliferative neoplasm increases with age.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215  }} </ref> The average age of diagnosis is 60-70.
 
===Gender===
===Gender===
Males are more commonly affected with  myeloproliferative neoplasm than females.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215  }} </ref> However, females are more likely to be affected by the abdominal symptoms of myeloproliferative neoplasm.<ref name="pmid27540137">{{cite journal| author=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S et al.| title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 85-93 | pmid=27540137 | doi=10.3324/haematol.2016.149559 | pmc=5210236 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27540137  }} </ref> Females are also more likely to develop thrombocytopenia than males.<ref name="pmid27540137">{{cite journal| author=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S et al.| title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 85-93 | pmid=27540137 | doi=10.3324/haematol.2016.149559 | pmc=5210236 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27540137  }} </ref>. Females have a shorter disease duration.
Males are more commonly affected with  myeloproliferative neoplasm than females.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215  }} </ref> However, females are more likely to be affected by the abdominal symptoms of myeloproliferative neoplasm.<ref name="pmid27540137">{{cite journal| author=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S et al.| title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 85-93 | pmid=27540137 | doi=10.3324/haematol.2016.149559 | pmc=5210236 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27540137  }} </ref> Females are also more likely to develop thrombocytopenia than males.<ref name="pmid27540137">{{cite journal| author=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S et al.| title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 85-93 | pmid=27540137 | doi=10.3324/haematol.2016.149559 | pmc=5210236 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27540137  }} </ref>. Females have a shorter disease duration.

Revision as of 02:52, 25 June 2018

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm epidemiology and demographics

on Myeloproliferative neoplasm epidemiology and demographics

Myeloproliferative neoplasm epidemiology and demographics in the news

Blogs on Myeloproliferative neoplasm epidemiology and demographics

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

The incidence of myeloproliferative neoplasm is approximately 2.3-7.8 per 100,000 individuals worldwide.[1] [2]

Epidemiology and Demographics

Incidence

The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide.[1] There are varying incidences for the different subtypes of myeloproliferative neoplasm. The incidence of polycythemia vera is 2 per 100,000 individuals.[3]

Age

The prevalence of myeloproliferative neoplasm increases with age.[4] The average age of diagnosis is 60-70.

Gender

Males are more commonly affected with myeloproliferative neoplasm than females.[4] However, females are more likely to be affected by the abdominal symptoms of myeloproliferative neoplasm.[5] Females are also more likely to develop thrombocytopenia than males.[5]. Females have a shorter disease duration.

Race

The prevalence of myeloproliferative neoplasm does not vary by race.[4]

References

  1. 1.0 1.1 Centers for Disease Control and Prevention. WTC Health Program.Myeloid Malignancieshttp://www.cdc.gov/wtc/pdfs/WTCHP_PP_MyeloidMalignancies_02012014.pdf
  2. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR (2010). "Autoimmunity and the risk of myeloproliferative neoplasms". Haematologica. 95 (7): 1216–20. doi:10.3324/haematol.2009.020412. PMC 2895049. PMID 20053870.
  3. Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S (2015). "Ruxolitinib for the treatment of patients with polycythemia vera". Expert Rev Hematol. 8 (4): 391–401. doi:10.1586/17474086.2015.1045869. PMC 4627585. PMID 25980454.
  4. 4.0 4.1 4.2 Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA; et al. (2008). "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs". Blood. 112 (1): 45–52. doi:10.1182/blood-2008-01-134858. PMID 18443215.
  5. 5.0 5.1 Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S; et al. (2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.

Template:WH Template:WS